Impact of genetic markers on treatment of non-small cell lung cancer.
Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients.
Published In/Presented At
Lamparella, N., Barochia, A., & Almokadem, S. (2013). Impact of genetic markers on treatment of non-small cell lung cancer. Advances in experimental medicine and biology, 779, 145–164. https://doi.org/10.1007/978-1-4614-6176-0_6
Medicine and Health Sciences
Department of Medicine, Hematology-Medical Oncology Division